J Craig Venter

This inventor holds 37 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Synthetic Genomics. Top assignees: Synthetic Genomics, Inc., Glaxosmithkline Biologicals Sa, Applera Corporation. Active years: 2002-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: J Craig Venter. Retrieved from https://idiyas.com/inventor/j-craig-venter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 4)

% Patents Active = 64.9

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 9)

Average Co-Inventor Count = 6.1

ph-index = 12

Forward Citations = 878(Granted Patents)

Location History:

Rockville, MD (US) (2003 - 2005)
Queenstown, MD (US) (2005)
Potomac, MD (US) (2002 - 2016)
Alexandria, VA (US) (2016)
La Jolla, CA (US) (2011 - 2023)

Company Filing History:

12 out of 79

Synthetic Genomics, Inc.

patents

4 out of 545

Glaxosmithkline Biologicals Sa

Telesis Bio Inc. (Formerly Known as Codex Dna, Inc.)

patents

7. 2 out of 676

Human Genome Sciences, Inc.

patents

8. 1 out of 20

J. Craig Venter Institute

patents

9. 1 out of 3,801

Johns Hopkins University

Novartis Vaccines & Diagnostics, Gmbh

14. 6 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Synthetic Genomes

Digital To Biological Converter

Nucleic Acid Assembly

Genome Installation

Cloning Techniques

Microbial Cultivation

Methane Production

Polymorphisms Detection

Haemophilus Influenzae

Mycoplasma Genitalium

Genomic Sequences

Biogenic Production

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12589396 - DIGITAL TO BIOLOGICAL CONVERTER (2026-03-31),

2. 12371724 - Methods for in vitro joining and combinatorial assembly of nucleic acid molecules (2025-07-29),

3. 12234450 - Generation of synthetic genomes (2025-02-25),

4. 11618029 - Digital to biological converter (2023-04-04),

5. 11408020 - Methods for in vitro joining and combinatorial assembly of nucleic acid molecules (2022-08-09),

6. 11085037 - Generation of synthetic genomes (2021-08-10),

7. 11027282 - Digital to biological converter (2021-06-08),

8. 10626429 - Methods for in vitro joining and combinatorial assembly of nucleic acid molecules (2020-04-21),

9. 10266865 - Methods for in vitro joining and combinatorial assembly of nucleic acid molecules (2019-04-23),

10. 10041060 - Method of nucleic acid cassette assembly (2018-08-07),

11. 9718060 - Digital to biological converter (2017-08-01),

12. 9593329 - Assembly of large nucleic acids (2017-03-14),

13. 9556413 - System and methods for anaerobic environmental microbial compartmentalized cultivation (2017-01-31),

14. 9481880 - Methods of genome installation in a recipient host cell (2016-11-01),

15. 9434974 - Installation of genomes or partial genomes into cells or cell-like systems (2016-09-06),

Title: The Innovator J. Craig Venter

Introduction: J. Craig Venter is a renowned American biologist and entrepreneur, known for his groundbreaking contributions to genomics and biotechnology. He is a leading figure in the field of synthetic biology and has made significant advancements in the study of the human genome.

Latest Patents: J. Craig Venter holds several patents related to genomics, DNA sequencing technologies, and synthetic life forms. His innovative work has paved the way for new developments in personalized medicine and biotechnological applications.

Career Highlights: Venter is the founder of several biotechnology companies, including Celera Genomics and Synthetic Genomics. He played a pivotal role in the Human Genome Project and was instrumental in sequencing the first human genome. His work has revolutionized the field of genomics and has had a profound impact on scientific research.

Collaborations: Throughout his career, J. Craig Venter has collaborated with leading scientists, researchers, and institutions around the world. His collaborative efforts have led to groundbreaking discoveries in genomics, biotechnology, and synthetic biology.

Conclusion: J. Craig Venter's pioneering work in genomics and biotechnology has earned him international recognition and acclaim. His innovative contributions continue to shape the future of scientific research and have opened up new possibilities in the fields of medicine, biotechnology, and beyond.

Profile summary based on public USPTO records.